MedTrace Logo

EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer

NCT02183870 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2022-06-16

No results posted yet for this study

Summary

EUCROSS is a phase II trial to evaluate the efficacy and safety of crizotinib in patients with adenocarcinoma of the lung harbouring ROS1 translocations. Patients will be treated with 250mg crizotinib bid until progression or intolerable toxicity.

Conditions

Interventions

DRUG

Crizotinib

250mg crizotinib bid until end of treatment

Sponsors & Collaborators

  • Spanish Lung Cancer Group

    collaborator OTHER

  • Pfizer

    collaborator INDUSTRY

  • University of Cologne

    lead OTHER

Principal Investigators

  • Juergen Wolf, Prof. Dr. med. · Uniklinik Köln, Department I for Internal Medicine, LCGC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2018-07-24
Completion
2020-02-29

Countries

  • Germany
  • Spain
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02183870 on ClinicalTrials.gov